Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2022

Treatment patterns and long-term survival outcomes for patients with stage III non=small cell lung cancer - a retrospective study (#282)

Seema Dr Kumari 1 , Deme Dr Karikios 1 2 , Roland Dr Yeghiaian-Alvandi 3 , Peter Dr Flynn 4 , Lucy Prof Morgan 1 5 , Lisa Kay 6 , Pei Dr Ding 1 2
  1. Sydney Medical School, University of Sydney, Camperdown, New South Wales, Australia
  2. Medical Oncology, Nepean Hospital Cancer Care Centre, Kingswood, New South Wales, Australia
  3. Radiation Oncology, Nepean Hospital Cancer Care Centre, Kingswood, New South Wales, Australia
  4. Surgical Department, Nepean Hospital, Kingswood, New South Wales, Australia
  5. Respiratory and Sleep Medicine, Nepean Hospital, Kingswood, New South Wales, Australia
  6. Nepean Cancer Research Biobank, Nepean Hospital, Kingswood, New South Wales, Australia

Aim: Lung cancer is the leading cause of cancer-related deaths in Australia with poor long-term survival outcomes. Stage III NSCLC is a highly heterogenous group with diverse tumour characteristics and multiple, possible treatment options. We present retrospective data on patient characteristics, treatment patterns and long-term outcomes in stage III NSCLC patients treated at a single cancer centre in NSW, Australia.

 

Methods: Stage III NSCLC patients were identified from the ‘Nepean Cancer Research Biobank’. Patient demographics, cancer-related information and long-term follow-up data were collected and analyzed.

 

Results: 88 patients were eligible for the study having their diagnosis established between March 2012 and April 2020, with 61% of them diagnosed as stage IIIA, 35% IIIB and 4% IIIC. Induction chemotherapy was administered in 20% of the patients. 48% of the study population underwent surgery and 38% underwent CCRT. Both median PFS and OS were superior in stage IIIA patients in comparison to stage IIIB (and IIIC) patients (22 versus 11 months, p=0.018 and 58 versus 19 months, p=0.048 respectively). Patients who were younger (<65 years old), good ECOG performance status (ECOG PS <2) and females had better prognosis on univariate analysis. There was a non-statistically significant trend towards better median OS with CCRT in comparison to surgery (58 versus 37 months, p=0.87).

 

Conclusion: We have presented some real word data from the past decade around the treatment patterns and long-term outcomes in stage III NSCLC patients. Equally, more robust, prospective studies would help delineate the optimal treatment modality in these patients who still face a dismal prognosis.